Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165490 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00165490: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00165490 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165490, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG Irinotecan
- PROCEDURE Surgery
- DEVICE Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT00165490 record still lists
NCT00165490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00165490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00165490 about?
NCT00165490 is a clinical study titled "Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer". The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
What is the current status of trial NCT00165490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2004-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00165490?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), Irinotecan (DRUG), Surgery (PROCEDURE), Radiation therapy (DEVICE).
Who is sponsoring clinical trial NCT00165490?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00165490's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia